Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 12, 2022

FDA approves Genentech’s sNDA for influenza therapy in children

The US Food and Drug Administration (FDA) has approved Genentech’s supplemental new drug application (sNDA) for xofluza (baloxavir marboxil) to treat influenza in children.

Xofluza is indicated to treat acute uncomplicated influenza in children aged five to less than 12 years. Credit: Mladen Borisov on Unsplash.